Literature DB >> 10509609

The yellow mouse obesity syndrome and mechanisms of agouti-induced obesity.

N M Moussa1, K J Claycombe.   

Abstract

The yellow mouse obesity syndrome is due to dominant mutations at the Agouti locus, which is characterized by obesity, hyperinsulinemia, insulin resistance, hyperglycemia, hyperleptinemia, increased linear growth, and yellow coat color. This syndrome is caused by ectopic expression of Agouti in multiple tissues. Mechanisms of Agouti action in obesity seem to involve, at least in part, competitive melanocortin antagonism. Both central and peripheral effects have been implicated in Agouti-induced obesity. An Agouti-Related Protein (AGRP) has been described recently. It has been shown to be expressed in mice hypothalamus and to act similarly to agouti as a potent antagonist to central melanocortin receptor MC4-R, suggesting that AGRP is an endogenous MC4-R ligand. Mice lacking MC4-R become hyperphagic and develop obesity, implying that agouti may lead to obesity by interfering with MC4-R signaling in the brain and consequently regulating food intake. Furthermore, food intake is inhibited by intracerebroventricular injection of a potent melanocortin agonist and was reversed by administration of an MC4-R antagonist. The direct cellular actions of Agouti include stimulation of fatty acid and triglyceride synthesis via a Ca(2+)-dependent mechanism. Agouti and insulin act in an additive manner to increase lipogenesis. This additive effect of agouti and insulin is demonstrated by the necessity of insulin in eliciting weight gain in transgenic mice expressing agouti specifically in adipose tissue. This suggests that agouti expression in adipose tissue combined with hyperinsulinemia may lead to increased adiposity. The roles of melanocortin receptors or agouti-specific receptor(s) in agouti regulation of adipocyte metabolism and other peripheral effects remain to be determined. In conclusion, both central and peripheral actions of agouti contribute to the yellow mouse obesity syndrome and this action is mediated at least in part by antagonism with melanocortin receptors and/or regulation of intracellular calcium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509609     DOI: 10.1002/j.1550-8528.1999.tb00440.x

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  7 in total

Review 1.  Childhood obesity.

Authors:  Joan C Han; Debbie A Lawlor; Sue Y S Kimm
Journal:  Lancet       Date:  2010-05-05       Impact factor: 79.321

Review 2.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

3.  Metabolic parameters and functional state of hypothalamic signaling systems in AY/a mice with genetic predisposition to obesity and the effect of metformin.

Authors:  K V Derkach; I O Zakharova; I V Romanova; I I Zorina; A L Mikhrina; A O Shpakov
Journal:  Dokl Biochem Biophys       Date:  2018-01-03       Impact factor: 0.788

4.  Epigenome modulated xenobiotic detoxification pathways control DMBA-induced breast cancer in agouti Avy/a mice.

Authors:  Simbarashe Mazambani; Madeleine Morris; Venugopalan Cheriyath
Journal:  Epigenetics       Date:  2019-05-09       Impact factor: 4.528

5.  Suppression of body fat accumulation in myostatin-deficient mice.

Authors:  Alexandra C McPherron; Se-Jin Lee
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

6.  Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis.

Authors:  Lei Huang; Jehnan Liu; Xiao-Ou Zhang; Katelyn Sibley; Sonia M Najjar; Mary M Lee; Qiong Wu
Journal:  J Biol Chem       Date:  2018-05-17       Impact factor: 5.157

7.  Loss of odor-induced c-Fos expression of juxtaglomerular activity following maintenance of mice on fatty diets.

Authors:  Erminia Fardone; Arda B Celen; Nicholas A Schreiter; Nicolas Thiebaud; Melissa L Cooper; Debra Ann Fadool
Journal:  J Bioenerg Biomembr       Date:  2018-09-11       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.